Anthracycline cardiotoxicity

Bibliography

• LEFRAK EA, PITHA J, ROSENHEIM S, GOTTLIEB JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer (1973) 32:302-314.
   PubMed Web of Science ®Google Scholar
• VON HOFF DD, LAYARD MW, BASA P et al.: Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. (1979) 91:710-717.
   PubMed Web of Science ®Google Scholar
• TAN C, TASAKA H, YU KP, MURPHY ML, KARNOFSKY DA: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer (1967) 20:333-353.
   PubMed Web of Science ®Google Scholar
• BONADONNA G, MONFARDINI S: Cardiac toxicity of daunorubicin. Lancet (1969) 1:837.
   PubMed Web of Science ®Google Scholar
• DI MARCO A, GAETANI M, SCARPINATO B: Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother. Rep. (1969) 53:33-37.
   PubMedGoogle Scholar
• PRAGA C, BERETTA G, VIGO PL et al.: Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat. Rep. (1979) 63:827-834.
   PubMedGoogle Scholar
• HARRISON DT, SANDERS LA: Pericarditis in a case of early daunorubicin cardiomyopathy. Ann. Intern. Med. (1976) 85:339-341.
   PubMed Web of Science ®Google Scholar
• MANCUSO L, MARCHI S, CANONICO A: Dynamic left ventricular outflow obstruction and myocardial infarction following doxorubicin administration in a woman affected by unsuspected hypertrophic cardiomyopathy. Cancer Treat. Rep. (1985) 69:241-244.
   PubMedGoogle Scholar
• STEINBERG JS, COHEN AJ, WASSERMAN AG, COHEN P, ROSS AM: Acute arrhythmogenicity of doxorubicin administration. Cancer (1987) 60:1213-1218.
   PubMed Web of Science ®Google Scholar
• O’BRYAN RM, LUCE JK, TALLEY RW, GOTTLIEB JA, BAKER LH, BONADONNA G: Phase II evaluation of adriamycin in human neoplasia. Cancer (1973) 32:1-8.
   PubMed Web of Science ®Google Scholar
• WORTMAN JE, LUCAS VS Jr, SCHUSTER E, THIELE D, LOGUE GL: Sudden death during doxorubicin administration. Cancer (1979) 44:1588-1591.
   PubMed Web of Science ®Google Scholar
• MINOW RA, BENJAMIN RS, LEE ET, GOTTLIEB JA: Adriamycin cardiomyopathy-risk factors. Cancer (1977) 39:1397-1402.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, LIPSITZ SR, SALLAN SE et al.: Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. (2005) 23:2629-2636.
   PubMed Web of Science ®Google Scholar
• STEINHERZ LJ, STEINHERZ PG, TAN CT, HELLER G, MURPHY ML: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA (1991) 266:1672-1677.
   PubMed Web of Science ®Google Scholar
• STEINHERZ LJ, STEINHERZ PG, TAN C: Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med. Pediatr. Oncol. (1995) 24:352-361.
   PubMedGoogle Scholar
• LIPSHULTZ SE, COLAN SD, GELBER RD, PEREZ-ATAYDE AR, SALLAN SE, SANDERS SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. (1991) 324:808-815.
   PubMed Web of Science ®Google Scholar
• CORTES EP, GUPTA M, CHOU C, AMIN VC, FOLKERS K: Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat. Rep. (1978) 62:887-891.
   PubMedGoogle Scholar
• BRISTOW MR, BILLINGHAM ME, MASON JW, DANIELS JR: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat. Rep. (1978) 62:873-879.
   PubMedGoogle Scholar
• BRISTOW MR, MASON JW, BILLINGHAM ME, DANIELS JR: Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann. Intern. Med. (1978) 88:168-175.
   PubMed Web of Science ®Google Scholar
• BILLINGHAM ME, BRISTOW MR, GLATSTEIN E, MASON JW, MASEK MA, DANIELS JR: Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am. J. Surg. Pathol. (1977) 1:17-23.
   PubMed Web of Science ®Google Scholar
• GILLADOGA AC, MANUEL C, TAN CT, WOLLNER N, STERNBERG SS, MURPHY ML: The cardiotoxicity of adriamycin and daunomycin in children. Cancer (1976) 37:1070-1078.
   PubMed Web of Science ®Google Scholar
• PROUT MN, RICHARDS MJ, CHUNG KJ, JOO P, DAVIS HL Jr: Adriamycin cardiotoxicity in children: case reports, literature review, and risk factors. Cancer (1977) 39:62-65.
   PubMed Web of Science ®Google Scholar
• MERRILL J, GRECO FA, ZIMBLER H, BRERETON HD, LAMBERG JD, POMEROY TC: Adriamycin and radiation: synegistic cardiotoxicity. Ann. Intern. Med. (1975) 82:122-123.
   PubMed Web of Science ®Google Scholar
• PIHKALA J, SAARINEN UM, LUNDSTROM U et al.: Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur. J. Cancer (1996) 32A:97-103.
   PubMed Web of Science ®Google Scholar
• MINOW RA, GOTTLIEB JA: Adriamycin cardiotoxicity. Ann. Intern. Med. (1975) 82:855-856.
   PubMedGoogle Scholar
• RINEHART JJ, LEWIS RP, BALCERZAK SP: Adriamycin cardiotoxicity in man. Ann. Intern. Med. (1974) 81:475-478.
   PubMed Web of Science ®Google Scholar
• KRISCHER JP, EPSTEIN S, CUTHBERTSON DD, GOORIN AM, EPSTEIN ML, LIPSHULTZ SE: Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J. Clin. Oncol. (1997) 15:1544-1552.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, LIPSITZ SR, MONE SM et al.: Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med. (1995) 332:1738-1743.
   PubMed Web of Science ®Google Scholar
• SILBER JH, JAKACKI RI, LARSEN RL, GOLDWEIN JW, BARBER G: Increased risk of cardiac dysfunction after anthracyclines in girls. Med. Pediatr. Oncol. (1993) 21:477-479.
   PubMedGoogle Scholar
• EWER MS, JAFFE N, RIED H, ZIETZ HA, BENJAMIN RS: Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Med. Pediatr. Oncol. (1998) 31:512-515.
   PubMedGoogle Scholar
• GIANTRIS A, ABDURRAHMAN L, HINKLE A, ASSELIN B, LIPSHULTZ SE: Anthracycline-induced cardiotoxicity in children and young adults. Crit. Rev. Oncol. Hematol. (1998) 27:53-68.
   PubMed Web of Science ®Google Scholar
• HASAN S, DINH K, LOMBARDO F, KARK J: Doxorubicin cardiotoxicity in African Americans. J. Natl. Med. Assoc. (2004) 96:196-199.
   PubMed Web of Science ®Google Scholar
• DOYLE JJ, NEUGUT AI, JACOBSON JS, GRANN VR, HERSHMAN DL: Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J. Clin. Oncol. (2005) 23:8597-8605.
   PubMed Web of Science ®Google Scholar
• BENJAMIN RS, WIERNIK PH, BACHUR NR: Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Med. Pediatr. Oncol. (1975) 1:63-76.
   PubMedGoogle Scholar
• KIM YD, LEES DE, LAKE CR et al.: Hyperthermia potentiates doxorubicin-related cardiotoxic effects. JAMA (1979) 241:1816-1817.
   PubMed Web of Science ®Google Scholar
• SWAIN SM, WHALEY FS, EWER MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer (2003) 97:2869-2879.
   PubMed Web of Science ®Google Scholar
• PEREZ EA, SUMAN VJ, DAVIDSON NE et al.: Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J. Clin. Oncol. (2004) 22:3700-3704.
   PubMed Web of Science ®Google Scholar
• SHAPIRO CL, HARDENBERGH PH, GELMAN R et al.: Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J. Clin. Oncol. (1998) 16:3493-3501.
   PubMed Web of Science ®Google Scholar
• ZAMBETTI M, MOLITERNI A, MATERAZZO C et al.: Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J. Clin. Oncol. (2001) 19:37-43.
   PubMed Web of Science ®Google Scholar
• KREMER LC, VAN DALEN EC, OFFRINGA M, VOUTE PA: Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann. Oncol. (2002) 13:503-512.
   PubMed Web of Science ®Google Scholar
• KREMER LC, VAN DER PAL HJ, OFFRINGA M, VAN DALEN EC, VOUTE PA: Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann. Oncol. (2002) 13:819-829.
   PubMed Web of Science ®Google Scholar
• LIMAT S, DEMESMAY K, VOILLAT L et al.: Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma. Ann. Oncol. (2003) 14:277-281.
   PubMed Web of Science ®Google Scholar
• NOUSIAINEN T, JANTUNEN E, VANNINEN E, HARTIKAINEN J: Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br. J. Cancer (2002) 86:1697-1700.
   PubMed Web of Science ®Google Scholar
• VON HOFF DD, ROZENCWEIG M, LAYARD M, SLAVIK M, MUGGIA FM: Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am. J. Med. (1977) 62:200-208.
   PubMed Web of Science ®Google Scholar
• GOORIN AM, CHAUVENET AR, PEREZ-ATAYDE AR, CRUZ J, MCKONE R, LIPSHULTZ SE: Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J. Pediatr. (1990) 116:144-147.
   PubMed Web of Science ®Google Scholar
• SORENSEN K, LEVITT GA, BULL C, DORUP I, SULLIVAN ID: Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer (2003) 97:1991-1998.
   PubMed Web of Science ®Google Scholar
• NYSOM K, HOLM K, LIPSITZ SR et al.: Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J. Clin. Oncol. (1998) 16(2):545-550.
   PubMed Web of Science ®Google Scholar
• PEIN F, SAKIROGLU O, DAHAN M et al.: Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br. J. Cancer (2004) 91:37-44.
   PubMed Web of Science ®Google Scholar
• BROUWER CA, GIETEMA JA, VAN DEN BERG MP et al.: Long-term cardiac follow-up in survivors of a malignant bone tumour. Ann. Oncol. (2006) (Epub ahead of print).
   Google Scholar
• KREMER LC, VAN DALEN EC, OFFRINGA M, OTTENKAMP J, VOUTE PA: Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J. Clin. Oncol. (2001) 19:191-196.
   PubMed Web of Science ®Google Scholar
• SORENSEN K, LEVITT G, SEBAG-MONTEFIORE D, BULL C, SULLIVAN I: Cardiac function in Wilms’ tumor survivors. J. Clin. Oncol. (1995) 13:1546-1556.
   PubMed Web of Science ®Google Scholar
• GANZ WI, SRIDHAR KS, GANZ SS, GONZALEZ R, CHAKKO S, SERAFINI A: Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology (1996) 53:461-470.
   PubMed Web of Science ®Google Scholar
• MCKILLOP JH, BRISTOW MR, GORIS ML, BILLINGHAM ME, BOCKEMUEHL K: Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am. Heart J. (1983) 106:1048-1056.
   PubMed Web of Science ®Google Scholar
• EWER MS: Exercise echocardiography reflects cumulative anthracycline exposure during childhood. Pediatr. Blood Cancer (2004) 42:554-555.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RG, MCKENZIE WB, ALEXANDER J et al.: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am. J. Med. (1987) 82:1109-1118.
   PubMed Web of Science ®Google Scholar
• DRUCK MN, GULENCHYN KY, EVANS WK et al.: Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer (1984) 53:1667-1674.
   PubMed Web of Science ®Google Scholar
• ALEXANDER J, BERGER HJ, ZARET BL: Testing for doxorubicin cardiotoxicity. N. Engl. J. Med. (1979) 300:1393.
   PubMedGoogle Scholar
• ALEXANDER J, DAINIAK N, BERGER HJ et al.: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N. Engl. J. Med. (1979) 300(6):278-283.
   PubMed Web of Science ®Google Scholar
• GOTTDIENER JS, MATHISEN DJ, BORER JS et al.: Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann. Intern. Med. (1981) 94:430-435.
   PubMed Web of Science ®Google Scholar
• RITCHIE JL, SINGER JW, THORNING D, SORENSEN SG, HAMILTON GW: Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer (1980) 46:1109-1116.
   PubMed Web of Science ®Google Scholar
• MORGAN GW, MCILVEEN BM, FREEDMAN A, MURRAY IP: Radionuclide ejection fraction in doxorubicin cardiotoxicity. Cancer Treat. Rep. (1981) 65:629-638.
   PubMedGoogle Scholar
• JAKACKI RI, LARSEN RL, BARBER G, HEYMAN S, FRIDMAN M, SILBER JH: Comparison of cardiac function tests after anthracycline therapy in childhood. Implications for screening. Cancer (1993) 72:2739-2745.
   PubMed Web of Science ®Google Scholar
• SORENSEN K, LEVITT G, BULL C, CHESSELLS J, SULLIVAN I: Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J. Clin. Oncol. (1997) 15:61-68.
   PubMed Web of Science ®Google Scholar
• HUTTER JJ Jr, SAHN DJ, WOOLFENDEN JM, CARNAHAN Y: Evaluation of the cardiac effects of doxorubicin by serial echocardiography. Am. J. Dis. Child. (1981) 135:653-657.
   PubMedGoogle Scholar
• KUECHERER HF, RUFFMANN K, SCHAEFER E, KUEBLER W: Doppler echocardiographic assessment of left ventricular filling dynamics in patients with coronary heart disease and normal systolic function. Eur. Heart J. (1988) 9:649-656.
   PubMed Web of Science ®Google Scholar
• ZARICH SW, ARBUCKLE BE, COHEN LR, ROBERTS M, NESTO RW: Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J. Am. Coll. Cardiol. (1988) 12:114-120.
   PubMed Web of Science ®Google Scholar
• STODDARD MF, SEEGER J, LIDDELL NE, HADLEY TJ, SULLIVAN DM, KUPERSMITH J: Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J. Am. Coll. Cardiol. (1992) 20:62-69.
   PubMed Web of Science ®Google Scholar
• EWER MS, ALI MK, GIBBS HR et al.: Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta. Oncol. (1994) 33:645-649.
   PubMed Web of Science ®Google Scholar
• SUNG RY, HUANG GY, SHING MK et al.: Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int. J. Cardiol. (1997) 60:239-248.
   PubMed Web of Science ®Google Scholar
• TJEERDSMA G, MEINARDI MT, VAN DER GRAAF WT et al.: Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart (1999) 81:419-423.
   PubMed Web of Science ®Google Scholar
• DORUP I, LEVITT G, SULLIVAN I, SORENSEN K: Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function. Heart (2004) 90:1214-1216.
   PubMed Web of Science ®Google Scholar
• BAUCH M, ESTER A, KIMURA B, VICTORICA BE, KEDAR A, PHILLIPS MI: Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer (1992) 69:1492-1497.
   PubMed Web of Science ®Google Scholar
• NOUSIAINEN T, VANNINEN E, JANTUNEN E et al.: Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J. Intern. Med. (2002) 251:228-234.
   PubMed Web of Science ®Google Scholar
• NOUSIAINEN T, VANNINEN E, JANTUNEN E et al.: Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients. Clin. Sci. (Lond.) (2001) 101:601-607.
   PubMed Web of Science ®Google Scholar
• RUSKOAHO H: Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol. Rev. (1992) 44:479-602.
   PubMed Web of Science ®Google Scholar
• LEVIN ER, GARDNER DG, SAMSON WK: Natriuretic peptides. N. Engl. J. Med. (1998) 339:321-328.
   PubMed Web of Science ®Google Scholar
• NOUSIAINEN T, JANTUNEN E, VANNINEN E, REMES J, VUOLTEENAHO O, HARTIKAINEN J: Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin’s lymphoma. Eur. J. Haematol. (1999) 62:135-141.
   PubMed Web of Science ®Google Scholar
• DAUGAARD G, LASSEN U, BIE P et al.: Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur. J. Heart Fail. (2005) 7:87-93.
   PubMed Web of Science ®Google Scholar
• SANDRI MT, SALVATICI M, CARDINALE D et al.: N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin. Chem. (2005) 51:1405-1410.
   PubMed Web of Science ®Google Scholar
• TIKANOJA T, RIIKONEN P, PERKKIO M, HELENIUS T: Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. Med. Pediatr. Oncol. (1998) 31:73-78.
   PubMedGoogle Scholar
• SUZUKI T, HAYASHI D, YAMAZAKI T et al.: Elevated B-type natriuretic peptide levels after anthracycline administration. Am. Heart J. (1998) 136:362-363.
   PubMed Web of Science ®Google Scholar
• CIOTTI R, UCCI G, BELOTTI G et al.: Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it? J. Clin. Oncol. (2001) 19:4269-4270.
   PubMed Web of Science ®Google Scholar
• MEINARDI MT, VAN VELDHUISEN DJ, GIETEMA JA et al.: Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J. Clin. Oncol. (2001) 19:2746-2753.
   PubMed Web of Science ®Google Scholar
• GERMANAKIS I, KALMANTI M, PARTHENAKIS F et al.: Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int. J. Cardiol. (2006) 108:212-215.
   PubMed Web of Science ®Google Scholar
• HORACEK JM, PUDIL R, TICHY M et al.: The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma (2005) 52:430-434.
   PubMed Web of Science ®Google Scholar
• CARDINALE D, SANDRI MT, MARTINONI A et al.: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J. Am. Coll. Cardiol. (2000) 36:517-522.
   PubMed Web of Science ®Google Scholar
• CARDINALE D, SANDRI MT, MARTINONI A et al.: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann. Oncol. (2002) 13:710-715.
   PubMed Web of Science ®Google Scholar
• KREMER LC, BASTIAANSEN BA, OFFRINGA M et al.: Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur. J. Cancer (2002) 38:686-689.
   PubMed Web of Science ®Google Scholar
• SANDRI MT, CARDINALE D, ZORZINO L et al.: Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin. Chem. (2003) 49:248-252.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, RIFAI N, SALLAN SE et al.: Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation (1997) 96:2641-2648.
   PubMed Web of Science ®Google Scholar
• MISSOV E, CALZOLARI C, DAVY JM, LECLERCQ F, ROSSI M, PAU B: Cardiac troponin I in patients with hematologic malignancies. Coron. Artery Dis. (1997) 8:537-541.
   PubMed Web of Science ®Google Scholar
• KILICKAP S, BARISTA I, AKGUL E et al.: cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann. Oncol. (2005) 16:798-804.
   PubMed Web of Science ®Google Scholar
• YAMASHITA J, OGAWA M, SHIRAKUSA T: Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int. J. Cancer (1995) 62:542-547.
   PubMed Web of Science ®Google Scholar
• BILLINGHAM ME, MASON JW, BRISTOW MR, DANIELS JR: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. (1978) 62:865-872.
   PubMedGoogle Scholar
• EWER MS, ALI MK, MACKAY B et al.: A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J. Clin. Oncol. (1984) 2:112-117.
   PubMed Web of Science ®Google Scholar
• ISNER JM, FERRANS VJ, COHEN SR et al.: Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am. J. Cardiol. (1983) 51:1167-1174.
   PubMed Web of Science ®Google Scholar
• KREMER LC, TIEL-VAN BUUL MM, UBBINK MC et al.: Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children. J. Clin. Oncol. (1999) 17:1208.
   PubMed Web of Science ®Google Scholar
• ESTORCH M, CARRIO I, MARTINEZ-DUNCKER D et al.: Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies. J. Clin. Oncol. (1993) 11:1264-1268.
   PubMed Web of Science ®Google Scholar
• ESTORCH M, CARRIO I, BERNA L et al.: Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J. Nucl. Med. (1990) 31:1965-1969.
   PubMed Web of Science ®Google Scholar
• HIROE M, OHTA Y, FUJITA N et al.: Myocardial uptake of 111In monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats. Morphological and hemodynamic findings. Circulation (1992) 86:1965-1972.
   PubMed Web of Science ®Google Scholar
• CARRIO I, ESTORCH M, BERNA L, LOPEZ-POUSA J, TABERNERO J, TORRES G: Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J. Nucl. Med. (1995) 36:2044-2049.
   PubMed Web of Science ®Google Scholar
• CARRIO I, LOPEZ-POUSA A, ESTORCH M et al.: Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J. Nucl. Med. (1993) 34:1503-1507.
   PubMed Web of Science ®Google Scholar
• ESTORCH M, CARRIO I, MARTINEZ-DUNCKER D et al.: Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies. J. Clin. Oncol. (1993) 11:1264-1268.
   PubMed Web of Science ®Google Scholar
• CARRIO I, ESTORCH M, BERNA L et al.: Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur. J. Nucl. Med. (1991) 18:806-812.
   PubMedGoogle Scholar
• NARULA J, STRAUSS HW, KHAW BA: Antimyosin positivity in doxorubicin cardiotoxicity: earlier than the conventional evidence. J. Nucl. Med. (1993) 34:1507-1509.
   PubMed Web of Science ®Google Scholar
• VALDES OLMOS RA, TEN BOKKEL HUININK WW, TEN HOEVE RF et al.: Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction. Ann. Oncol. (1994) 5:617-622.
   PubMed Web of Science ®Google Scholar
• VALDES OLMOS RA, TEN BOKKEL HUININK WW, TEN HOEVE RF et al.: Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur. J. Cancer (1995) 31A:26-31.
   PubMedGoogle Scholar
• HAHM S, DRESNER HS, PODWALL D et al.: DNA biomarkers antecede semiquantitative anthracycline cardiomyopathy. Cancer Invest. (2003) 21:53-67.
   PubMed Web of Science ®Google Scholar
• WASSMUTH R, LENTZSCH S, ERDBRUEGGER U et al.: Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging - a pilot study. Am. Heart J. (2001) 141:1007-1013.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N. Engl. J. Med. (1992) 327:685-691.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. (1991) 325:293-302.
   PubMed Web of Science ®Google Scholar
• PACKER M, COATS AJ, FOWLER MB et al.: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. (2001) 344:1651-1658.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353:9-13.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353:2001-2007.
   PubMed Web of Science ®Google Scholar
• HEIDENREICH PA, LEE TT, MASSIE BM: Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. (1997) 30(1):27-34.
   PubMed Web of Science ®Google Scholar
• LECHAT P, PACKER M, CHALON S, CUCHERAT M, ARAB T, BOISSEL JP: Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation (1998) 98:1184-1191.
   PubMed Web of Science ®Google Scholar
• JENSEN BV, NIELSEN SL, SKOVSGAARD T: Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet (1996) 347:297-299.
   PubMed Web of Science ®Google Scholar
• FAZIO S, PALMIERI EA, FERRAVANTE B, BONE F, BIONDI B, SACCA L: Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin. Cardiol. (1998) 21:777-779.
   PubMed Web of Science ®Google Scholar
• NOORI A, LINDENFELD J, WOLFEL E, FERGUSON D, BRISTOW MR, LOWES BD: Beta-blockade in adriamycin-induced cardiomyopathy. J. Card. Fail. (2000) 6:115-119.
   PubMed Web of Science ®Google Scholar
• MUKAI Y, YOSHIDA T, NAKAIKE R et al.: Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. Intern. Med. (2004) 43:1087-1088.
   PubMed Web of Science ®Google Scholar
• SILBER JH, CNAAN A, CLARK BJ et al.: Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. (2004) 22:820-828.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, LIPSITZ SR, SALLAN SE et al.: Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J. Clin. Oncol. (2002) 20:4517-4522.
   PubMed Web of Science ®Google Scholar
• NAKAMAE H, TSUMURA K, TERADA Y et al.: Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer (2005) 104:2492-2498.
   PubMed Web of Science ®Google Scholar
• LEVITT G, BUNCH K, ROGERS CA, WHITEHEAD B: Cardiac transplantation in childhood cancer survivors in Great Britain. Eur. J. Cancer (1996) 32A:826-830.
   PubMed Web of Science ®Google Scholar
• ARMITAGE JM, KORMOS RL, GRIFFITH BP, FRICKER FJ, HARDESTY RL: Heart transplantation in patients with malignant disease. J. Heart Transplant. (1990) 9:627-629.
   PubMedGoogle Scholar
• GRANDE AM, RINALDI M, SINELLI S, D’ARMINI AM, VIGANO M: Heart transplantation in chemotherapeutic dilated cardiomyopathy. Transplant. Proc. (2003) 35:1516-1518.
   PubMed Web of Science ®Google Scholar
• OLSON RD, MUSHLIN PS: Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. (1990) 4:3076-3086.
   PubMed Web of Science ®Google Scholar
• GIANNI L, ZWEIER JL, LEVY A, MYERS CE: Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen. J. Biol. Chem. (1985) 260:6820-6826.
   PubMed Web of Science ®Google Scholar
• WOLF MB, BAYNES JW: The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim. Biophys. Acta. (2006) 1760:267-271.
   PubMed Web of Science ®Google Scholar
• CHOW AY, CHIN C, DAHL G, ROSENTHAL DN: Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J. Clin. Oncol. (2006) 24:925-928.
   PubMed Web of Science ®Google Scholar
• ZHOU S, STARKOV A, FROBERG MK, LEINO RL, WALLACE KB: Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. (2001) 61:771-777.
   PubMed Web of Science ®Google Scholar
• KOTAMRAJU S, KALIVENDI SV, KONOREV E, CHITAMBAR CR, JOSEPH J, KALYANARAMAN B: Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis. Methods Enzymol. (2004) 378:362-382.
   PubMed Web of Science ®Google Scholar
• KOTAMRAJU S, KONOREV EA, JOSEPH J, KALYANARAMAN B: Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J. Biol. Chem. (2000) 275:33585-33592.
   PubMed Web of Science ®Google Scholar
• KALIVENDI SV, KOTAMRAJU S, ZHAO H, JOSEPH J, KALYANARAMAN B: Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J. Biol. Chem. (2001) 276:47266-47276.
   PubMed Web of Science ®Google Scholar
• NADAL-GINARD B, KAJSTURA J, ANVERSA P, LERI A: A matter of life and death: cardiac myocyte apoptosis and regeneration. J. Clin. Invest. (2003) 111:1457-1459.
   PubMed Web of Science ®Google Scholar
• WANG S, KOTAMRAJU S, KONOREV E, KALIVENDI S, JOSEPH J, KALYANARAMAN B: Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem. J. (2002) 367:729-740.
   PubMed Web of Science ®Google Scholar
• MINOTTI G, MENNA P, SALVATORELLI E, CAIRO G, GIANNI L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. (2004) 56:185-229.
   PubMed Web of Science ®Google Scholar
• FISHER PW, SALLOUM F, DAS A, HYDER H, KUKREJA RC: Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation (2005) 111:1601-1610.
   PubMed Web of Science ®Google Scholar
• SIMUNEK T, STERBA M, HOLECKOVA M et al.: Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. Biometals (2005) 18:163-169.
   PubMed Web of Science ®Google Scholar
• BRAMBILLA C, ROSSI A, BONFANTE V et al.: Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat. Rep. (1986) 70:261-266.
   PubMedGoogle Scholar
• JAIN KK, CASPER ES, GELLER NL et al.: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J. Clin. Oncol. (1985) 3:818-826.
   PubMed Web of Science ®Google Scholar
• PEREZ DJ, HARVEY VJ, ROBINSON BA et al.: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J. Clin. Oncol. (1991) 9:2148-2152.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. J. Clin. Oncol. (1988) 6:976-982.
   PubMed Web of Science ®Google Scholar
• FRENCH EPIRUBICIN STUDY GROUP: A prospective randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J. Clin. Oncol. (1988) 6:679-688.
   PubMed Web of Science ®Google Scholar
• NIELSEN D, JENSEN JB, DOMBERNOWSKY P et al.: Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J. Clin. Oncol. (1990) 8:1806-1810.
   PubMed Web of Science ®Google Scholar
• RYBERG M, NIELSEN D, SKOVSGAARD T, HANSEN J, JENSEN BV, DOMBERNOWSKY P: Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J. Clin. Oncol. (1998) 16:3502-3508.
   PubMed Web of Science ®Google Scholar
• MEINARDI MT, VAN VELDHUISEN DJ, GIETEMA JA et al.: Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J. Clin. Oncol. (2001) 19:2746-2753.
   PubMed Web of Science ®Google Scholar
• BONNETERRE J, ROCHE H, KERBRAT P et al.: Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J. Clin. Oncol. (2004) 22:3070-3079.
   PubMed Web of Science ®Google Scholar
• FUMOLEAU P, ROCHE H, KERBRAT P et al.: French Adjuvant Study Group. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann. Oncol. (2006) 17:85-92.
   PubMed Web of Science ®Google Scholar
• LOPEZ M, CONTEGIACOMO A, VICI P et al.: A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer (1989) 64:2431-2436.
   PubMed Web of Science ®Google Scholar
• ANDERLINI P, BENJAMIN RS, WONG FC et al.: Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. (1995) 13:2827-2834.
   PubMed Web of Science ®Google Scholar
• TOFFOLI G, SORIO R, AITA P et al.: Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin. Cancer Res. (2000) 6:2279-2287.
   PubMed Web of Science ®Google Scholar
• CRIVELLARI D, LOMBARDI D, CORONA G et al.: Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a Phase II multi-institutional study with pharmacokinetic drug monitoring. Ann. Oncol. (2006) 17:807-812.
   PubMed Web of Science ®Google Scholar
• SHENKENBERG TD, VON HOFF DD: Mitoxantrone: a new anticancer drug with significant clinical activity. Ann. Intern. Med. (1986) 105:67-81.
   PubMed Web of Science ®Google Scholar
• UNVERFERTH DV, UNVERFERTH BJ, BALCERZAK SP, BASHORE TA, NEIDHART JA: Cardiac evaluation of mitoxantrone. Cancer Treat. Rep. (1983) 67:343-350.
   PubMedGoogle Scholar
• MATHER FJ, SIMON RM, CLARK GM, VON HOFF DD: Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group Phase II studies. Cancer Treat. Rep. (1987) 71:609-613.
   PubMedGoogle Scholar
• CROSSLEY RJ: Clinical safety and tolerance of mitoxantrone. Semin. Oncol. (1984) 11:54-58.
   PubMed Web of Science ®Google Scholar
• VAN DALEN EC, VAN DER PAL HJ, BAKKER PJ, CARON HN, KREMER LC: Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur. J. Cancer (2004) 40:643-652.
   PubMed Web of Science ®Google Scholar
• FORD JM, PANASCI L, LECLERC Y, MARGOLESE R: Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer. Cancer Treat. Rep. (1987) 71:921-925.
   PubMedGoogle Scholar
• STEWART DJ, PERRAULT DJ, MAROUN JA, LEFEBVRE BM: Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. Am. J. Clin. Oncol. (1987) 10:335-340.
   PubMed Web of Science ®Google Scholar
• JANMOHAMMED R, MILLIGAN DW: Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines. Br. J. Haematol. (1989) 71:292-293.
   PubMed Web of Science ®Google Scholar
• VON HERBAY A, DORKEN B, MALL G, KORBLING M: Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor. Klin. Wochenschr. (1988) 66:1175-1181.
   PubMedGoogle Scholar
• UMEMOTO M, KAWASAKI H, AZUMA E, KOMADA Y, ITO M, SAKURAI M: Bradycardia due to mitoxantrone exacerbated by previous anthracycline therapy. Am. J. Hematol. (1996) 52:327-328.
   PubMed Web of Science ®Google Scholar
• BENEKLI M, KARS A, GULER N: Mitoxantrone-induced bradycardia. Ann. Intern. Med. (1997) 126:409.
   PubMed Web of Science ®Google Scholar
• ROCK E, DEMICHELE A: Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J. Nutr. (2003) 133:3785S-3793S.
   PubMed Web of Science ®Google Scholar
• IARUSSI D, AURICCHIO U, AGRETTO A et al.: Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol. Aspects Med. (1994) 15: s207-s212.
   PubMed Web of Science ®Google Scholar
• KRAFT J, GRILLE W, APPELT M et al.: Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial. Haematol. Blood Transfus. (1990) 33:566-570.
   PubMedGoogle Scholar
• MILEI J, MARANTZ A, ALE J, VAZQUEZ A, BUCETA JE: Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study. Cancer Drug Deliv. (1987) 4:129-136.
   PubMedGoogle Scholar
• MYERS C, BONOW R, PALMERI S et al.: A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. (1983) 10:53-55.
   PubMed Web of Science ®Google Scholar
• WAGDI P, ROUVINEZ G, FLURI M et al.: [Cardioprotection in chemo- and radiotherapy for malignant diseases – an echocardiographic pilot study]. Schweiz. Rundsch. Med. Prax. (1995) 84:1220-1223.
   Google Scholar
• VAN DALEN EC, CARON HN, DICKINSON HO, KREMER LC: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. (2005) 1:CD003917.
   PubMedGoogle Scholar
• LI T, SINGAL PK: Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation (2000) 102:2105-2110.
   PubMed Web of Science ®Google Scholar
• STRAUSS M, ANSELMI G, HERMOSO T, TEJERO F: Carnitine promotes heat shock protein synthesis in adriamycin-induced cardiomyopathy in a neonatal rat experimental model. J. Mol. Cell Cardiol. (1998) 30:2319-2325.
   PubMed Web of Science ®Google Scholar
• YARIS N, CEVIZ N, COSKUN T, AKYTUZ C, BUYUKPAMUKCU M: Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. J. Exp. Clin. Cancer Res. (2002) 21:165-170.
   PubMed Web of Science ®Google Scholar
• DANESI F, MALAGUTI M, NUNZIO MD, MARANESI M, BIAGI PL, BORDONI A: Counteraction of adriamycin-induced oxidative damage in rat heart by selenium dietary supplementation. J. Agric. Food Chem. (2006) 54:1203-1208.
   PubMed Web of Science ®Google Scholar
• LI L, TAKEMURA G, LI Y et al.: Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation (2006) 113:535-543.
   PubMed Web of Science ®Google Scholar
• SAVARESE DM, SAVY G, VAHDAT L, WISCHMEYER PE, COREY B: Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat. Rev. (2003) 29:501-513.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE S, BANERJEE SK, MAULIK M, DINDA AK, TALWAR KK, MAULIK SK: Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. BMC Pharmacol. (2003) 3:16.
   Google Scholar
• WEISS AJ, METTER GE, FLETCHER WS, WILSON WL, GRAGE TB, RAMIREZ G: Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat. Rep. (1976) 60:813-822.
   PubMedGoogle Scholar
• WEISS AJ, MANTHEL RW: Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer (1977) 40:2046-2052.
   PubMed Web of Science ®Google Scholar
• CHLEBOWSKI RT, PAROLY WS, PUGH RP et al.: Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat. Rep. (1980) 64:47-51.
   PubMedGoogle Scholar
• TORTI FM, BRISTOW MR, HOWES AE et al.: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann. Intern. Med. (1983) 99:745-749.
   PubMed Web of Science ®Google Scholar
• VALDIVIESO M, BURGESS MA, EWER MS et al.: Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J. Clin. Oncol. (1984) 2:207-214.
   PubMed Web of Science ®Google Scholar
• LEGHA SS, BENJAMIN RS, MACKAY B et al.: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. (1982) 96:133-139.
   PubMed Web of Science ®Google Scholar
• HORTOBAGYI GN, FRYE D, BUZDAR AU et al.: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast Carcinoma. Cancer (1989) 63:37-45.
   PubMed Web of Science ®Google Scholar
• ZALUPSKI M, METCH B, BALCERZAK S et al.: Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J. Natl. Cancer Inst. (1991) 83:926-932.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, GIANTRIS AL, LIPSITZ SR et al.: Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J. Clin. Oncol. (2002) 20:1677-1682.
   PubMed Web of Science ®Google Scholar
• LEVITT GA, DORUP I, SORENSEN K, SULLIVAN I: Does anthracycline administration by infusion in children affect late cardiotoxicity? Br. J. Haematol. (2004) 124:463-468.
   PubMed Web of Science ®Google Scholar
• RAJAGOPALAN S, POLITI PM, SINHA BK, MYERS CE: Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. (1988) 48:4766-4769.
   PubMed Web of Science ®Google Scholar
• SPEYER JL, GREEN MD, ZELENIUCH-JACQUOTTE A et al.: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. (1992) 10:117-127.
   PubMed Web of Science ®Google Scholar
• KELLNER U, SEHESTED M, JENSEN PB, GIESELER F, RUDOLPH P: Culprit and victim – DNA topoisomerase II. Lancet Oncol. (2002) 3:235-243.
   PubMed Web of Science ®Google Scholar
• WEXLER LH, ANDRICH MP, VENZON D et al.: Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. (1996) 14:362-372.
   PubMed Web of Science ®Google Scholar
• SWAIN SM, WHALEY FS, GERBER MC, EWER MS, BIANCHINE JR, GAMS RA: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol. (1997) 15:1333-1340.
   PubMed Web of Science ®Google Scholar
• SWAIN SM, WHALEY FS, GERBER MC et al.: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. (1997) 15:1318-1332.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, RIFAI N, DALTON VM et al.: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med. (2004) 351:145-153.
   PubMed Web of Science ®Google Scholar
• MARTY M, ESPIE M, LLOMBART A, MONNIER A, RAPOPORT BL, STAHALOVA V: Multicenter randomized Phase III study of the cardioprotective effect of dexrazoxane (Cardioxane(R)) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann. Oncol. (2006) 17:614-622.
   PubMed Web of Science ®Google Scholar
• SEYMOUR L, BRAMWELL V, MORAN LA: Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev. Control (1999) 3:145-159.
   PubMedGoogle Scholar
• SCHUCHTER LM, HENSLEY ML, MEROPOL NJ, WINER EP: American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel: 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. (2002) 20:2895-2903.
   PubMed Web of Science ®Google Scholar
• CVETKOVIC RS, SCOTT LJ: Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs (2005) 65:1005-1024.
   PubMed Web of Science ®Google Scholar
• HIGUCHI Y, OTSU K, NISHIDA K et al.: Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J. Mol. Cell Cardiol. (2002) 34:233-240.
   PubMed Web of Science ®Google Scholar
• BOLAND MP, FOSTER SJ, O’NEILL LA: Daunorubicin activates NFkappaB and induces kappaB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells. J. Biol. Chem. (1997) 272:12952-12960.
   PubMed Web of Science ®Google Scholar
• WANG CY, MAYO MW, BALDWIN AS Jr: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (1996) 274:784-787.
   PubMed Web of Science ®Google Scholar
• TERGAONKAR V, BOTTERO V, IKAWA M, LI Q, VERMA IM: IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy. Mol. Cell Biol. (2003) 23:8070-8083.
   PubMed Web of Science ®Google Scholar
• BOLAND MP, FITZGERALD KA, O’NEILL LA: Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J. Biol. Chem. (2000) 275:25231-25238.
   PubMed Web of Science ®Google Scholar
• GABIZON AA: Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. (1992) 52:891-896.
   PubMed Web of Science ®Google Scholar
• RIVERA E: Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist (2003) 8:3-9.
   PubMed Web of Science ®Google Scholar
• O’BYRNE KJ, THOMAS AL, SHARMA RA et al.: A Phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br. J. Cancer (2002) 87:15-20.
   PubMed Web of Science ®Google Scholar
• FASSAS A, BUFFELS R, ANAGNOSTOPOULOS A et al.: Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a Phase I-II study. Br. J. Haematol. (2002) 116:308-315.
   PubMed Web of Science ®Google Scholar
• BATIST G, RAMAKRISHNAN G, RAO CS et al.: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. (2001) 19:1444-1454.
   PubMed Web of Science ®Google Scholar
• SHAPIRO CL, ERVIN T, WELLES L, AZARNIA N, KEATING J, HAYES DF: Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J. Clin. Oncol. (1999) 17:1435-1441.
   PubMed Web of Science ®Google Scholar
• BERRY G, BILLINGHAM M, ALDERMAN E et al.: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin. Ann. Oncol. (1998) 9:711-716.
   PubMed Web of Science ®Google Scholar
• SAFRA T, MUGGIA F, JEFFERS S et al.: Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. (2000) 11:1029-1033.
   PubMed Web of Science ®Google Scholar
• GABIZON AA, LYASS O, BERRY GJ, WILDGUST M: Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest. (2004) 22:663-669.
   PubMed Web of Science ®Google Scholar
• O’BRIEN ME, WIGLER N, INBAR M et al.; CAELYX Breast Cancer Study Group: Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. (2004) 15:440-449.
   PubMed Web of Science ®Google Scholar
• CHAN S, DAVIDSON N, JUOZAITYTE E et al.: Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann. Oncol. (2004) 15:1527-1534.
   PubMed Web of Science ®Google Scholar
• SEIDMAN A, HUDIS C, PIERRI MK et al.: Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. (2002) 20:1215-1221.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344:783-792.
   PubMed Web of Science ®Google Scholar
• CHIA S, CLEMONS M, MARTIN LA et al.: Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter Phase II trial. J. Clin. Oncol. (2006) 24:2773-2778.
   PubMed Web of Science ®Google Scholar
• CARDONICK E, IACOBUCCI A: Use of chemotherapy during human pregnancy. Lancet Oncol. (2004) 5:283-291.
   PubMed Web of Science ®Google Scholar
• PECCATORI F, MARTINELLI G, GENTILINI O, GOLDHIRSCH A: Chemotherapy during pregnancy: what is really safe? Lancet Oncol. (2004) 5:398.
   PubMed Web of Science ®Google Scholar
• AVILES A, NERI N, NAMBO MJ: Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy. Ann. Oncol. (2006) 17:286-288.
   PubMed Web of Science ®Google Scholar
• VAN CALSTEREN K, BERTELOOT P, HANSSENS M et al.: In utero exposure to chemotherapy: effect on cardiac and neurologic outcome. J. Clin. Oncol. (2006) 24:e16-e17.
   Web of Science ®Google Scholar